Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease

CompletedOBSERVATIONAL
Enrollment

3,482

Participants

Timeline

Start Date

June 1, 2013

Primary Completion Date

May 1, 2015

Study Completion Date

April 15, 2016

Conditions
Alzheimer's Desease
Interventions
DRUG

Donepezil Hydrochloride

Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.

Trial Locations (1)

Unknown

Multiple Locations

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02162251 - Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter